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Abstract: Autologous blood derived products, such as platelet-rich plasma (PRP) and platelet-rich
fibrin (PRF) are widely applied in regenerative therapies, in contrast to the drawbacks in their
application, mainly deriving from the preparation methods used. Eliminating the disadvantages of
both PRP and PRF, hyperacute serum (HAS) opens a new path in autologous serum therapy showing
similar or even improved regenerative potential at the same time. Despite the frequent experimental
and clinical use of PRP and HAS, their protein composition has not been examined thoroughly yet.
Thus, we investigated and compared the composition of HAS, serum, PRP and plasma products
using citrate and EDTA by simple laboratory tests, and we compared the composition of HAS, serum,
EDTA PRP and plasma by Proteome Profiler and ELISA assays. According to our results the natural
ionic balance was upset in both EDTA and citrate PRP as well as in plasma. EDTA PRP contained
significantly higher level of growth factors and cytokines, especially platelet derived angiogenic and
inflammatory proteins, that can be explained by the significantly higher number of platelets in EDTA
PRP. The composition analysis of blood derivatives revealed that although the preparation method of
PRP and HAS were similar, the ionic and protein composition of HAS could be advantageous for
cell function.
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1. Introduction
Autologous blood derived products, particularly platelet concentrates, are widely applied
nowadays in different regenerative therapies which include wound healing, orthopedics, and
dentistry [1–5]. Platelet derived growth factors are able to enhance soft and hard tissue regeneration
by increasing cell migration and proliferation, and decreasing the rate of inflammation [6,7]. The most
commonly used platelet concentrate products are PRP (platelet-rich plasma)—also known as first
generation blood product—and PRF (platelet-rich fibrin), which is known as second generation blood
product. PRP has a wide range of application in wound healing, cartilage, bone, musculoskeletal
regeneration, oral surgery, dentistry, and cosmetics [8–13]. Moreover, PRP has been successfully applied
in treating endometriosis, chronic skin ulcer and vitiligo in earlier studies [14,15]. Nevertheless, there
are some drawbacks of using PRP [16]. For example, the lack of uniformity in PRP preparation
methods [4,17] which is mainly caused by the treatment of blood with different anticoagulants like
EDTA and citrate, which are the most preferred ones in PRP preparation. The information in the
literature on the optimal anticoagulant for PRP preparation is contradictory. On the basis of previous
studies, both EDTA and citrate (sodium citrate, acid citrate dextrose) have a negative effect on the
balance of ionic content in the plasma fraction because of their chelating mechanism [18]. Higher
platelet numbers can be obtained by using EDTA compared to citrate [19,20], however the mean
platelet volume (MPV)—which is a marker of platelet function—can be higher than citrate using
EDTA [20]. Other studies have claimed that platelet aggregation was inhibited more efficiently by
using EDTA than acid citrate dextrose solution [19]. Using EDTA, spontaneous platelet activation can
be avoided because EDTA has a stronger complex capacity with divalent cations than citrate. For the
activation of citrate and EDTA, PRP thrombin and calcium–chloride or temperature activation can be
used. [21] The addition of bovine thrombin during PRP preparation may lead to cross-reaction with
human factor Va causing bleeding disorder, but it is more effective than activating PRP by repeated
freezing and thawing [16].
With PRF the major disadvantages of PRP can be avoided. In addition, growth factors and
cytokines are released from platelets over a longer period of time, whereas in PRP these factors are
released immediately into the site of application [22,23]. Nevertheless, PRF is not capable of replacing
PRP in all therapeutic areas because of its compact three-dimensional structure, which hinders its
application as an injection [24–26]. Consequently, PRF is mainly used for replacing injured tissues in
oral and dental surgery, orthopedics, and wound healing [27–31].
SPRF (serum from platelet-rich fibrin) or HAS (hyperacute serum) was developed to avoid the
limitations of both PRF and PRP. The preparation method is the same as in the case of PRF, but the
serum is squeezed out from the PRF clot at the end of the procedure [32]. Thus, it does not contain any
anticoagulant or thrombin, and the final product is liquid. Based on our previous results, HAS has a
better cell proliferative effect on mesenchymal stem cells, osteoblasts, and osteoarthritic chondrocytes
compared to EDTA PRP [33]. Furthermore, HAS promotes MSCs lineage shift towards the osteoblastic
line and results in a better preserved bone marrow structure in bone marrow explants compared to
EDTA PRP treatments [32,34].
Despite the positive results of HAS in cell proliferation and migration, the composition of HAS has
not been reported so far. However, angiogenic proteins were measured earlier both in HAS and PRP by
Proteome Profiler, showing that EDTA PRP has more angiopoietic components, whereas HAS has more
anti-angiopoietic components [35]. In the present study we investigated and compared the composition
of HAS, PRP, blood serum, and plasma to understand the differences in the cell proliferative and
regenerative effect of HAS and PRP. In the laboratory tests EDTA and citrate anticoagulated PRP were
also compared. However, due to the more homogenous blood fraction separation that was achieved
using EDTA, and based on the earlier cell culture experiments, the semi-quantitative and quantitative
analysis was only done with PRP that was anticoagulated with EDTA in order to allow consequent
results and interpretation.
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2. Results
First, we measured the concentration of relevant metal ions, inorganic phosphate, the activity of
ALP enzyme, and the quantity of cellular blood components in the serum and plasma samples by a
general laboratory test. EDTA and citrate PRP were activated by thrombin and CaCl2 with heparin
together to prevent coagulation, thus the chelation capacity of both K3EDTA and sodium citrate was
reduced in PRP.
The concentration of calcium ions was significantly higher in EDTA and citrate PRP, and lower
in EDTA and citrate plasma compared to the serum fractions. Both anticoagulants effectively chelate
calcium and citrate is more effective in forming complexes with magnesium ions. The level of potassium
ions was higher in EDTA plasma fractions due to the potassium content of K3EDTA. The concentration
of copper, zinc, and iron ions was also significantly lower in EDTA plasma and EDTA PRP due to the
chelating ability of K3EDTA. Sodium ion concentration was increased due to the sodium content of
citrate while phosphate content was only significantly influenced using citrate PRP. The activity of
ALP enzymes was also reduced significantly because EDTA naturally chelates Mg2+ and Zn2+ which
have a crucial role in the structural stability of ALP enzyme (Figure 1A).
Figure 1. Quantitative determination of the concentration of relevant ions and the activity of alkaline
phosphatase (ALP) enzyme (A) and the number of red blood cells, leukocytes and platelets in the serum
and plasma fractions (B), n = 4. The significance level was p > 0.05, where * means that p is between
0.01 and 0.05, ** means that p is between 0.01 and 0.001, and *** means that p is lower than 0.001.
Sodium citrate has a weaker complex capacity with divalent cations than EDTA, thus the ion
content of citrate plasma fractions was not influenced significantly except calcium ions, which were
added both to citrate and EDTA PRP for activation. Cellular blood components were measured before
activating PRP because activated platelets might have been disrupted. The number of leukocytes was
the highest in citrate PRP and the standard error of mean was high in the case of EDTA and citrate
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PRP as well. The number of platelets was higher in EDTA PRP compared to citrate PRP. The platelet
number was extremely low in EDTA and citrate plasma, serum and HAS. Mean platelet volume (MPV),
which is a marker of platelet function, was similar in EDTA and citrate PRP. (Figure 1B). For further
examination EDTA plasma and PRP were used because a higher number of platelets could be isolated
by EDTA than citrate with similar MPV values. Furthermore, EDTA enabled the most homogenous
separation and therefore EDTA was used as an anticoagulant in our previous studies where the cell
proliferation rate of different cell types was investigated.
For mapping the composition of serum, HAS, EDTA plasma, and PRP (Figure 2A), 138 different
known cytokines and growth factors were screened using antibody-based dot-blot assays. The results
were presented as relative values compared to the positive control for the secondary antibody. From
the 138 cytokines and growth factors selected as known paracrine mediators of tissue regeneration,
vascularization or inflammation, 82 proteins were neglected (AU < 2%) thus 56 proteins (AU > 2%) are
presented in Figure 2A [35]. The whole data set containing the 138 cytokines and growth factors is
shown in Table S1. We observed a general trend that the overall concentration of active molecules was
the highest in PRP, followed by HAS, plasma, and serum, respectively (see in Figure 2A and Table S1).
There were clear differences in the proteome profiler patterns of the blood derivatives, although the
proteome profiler is not reliable enough for quantitative measurements and for the statistic comparison
of the blood derivates. Thus, on the basis of these results and the literature [6,36–39] we set out to
quantify the key inflammation related cytokines and proteins with ELISA or Luminex assays.
Figure 2. Semi-quantitative Proteome Profiler analysis of serum, hyperacute serum (HAS), plasma,
and platelet-rich fibrin (PRP). On the bar chart proteins exceeding 2% (AU) of the total protein content
(A) are presented. The level of the top 10 angiogenic proteins and cytokines are presented on a heat
map. (B) The level of the proteins is expressed in % compared to the combined arbitrary unit of ANG
that was considered to be 100%. n = 8.
For quantitative protein analysis, Luminex and ELISA assays were used where systemic
pro-inflammatory molecules, complement system molecules, platelet-derived inflammation,
angiogenesis related molecules, and anti-inflammatory molecules were investigated. Lipocalin-2,
EMMPRIN (CD147), Osteopontin, IL-17A, and Chitinase-3-like protein 1 (CHI3L1) are similarly present
in all blood derivates. While CD97 and Myeloperoxidase (MPO) were higher in serum derivates,
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ALCAM was higher in plasma derivates. The concentration of CD40L was elevated in PRP compared
to HAS, and CRP was significantly higher in plasma than in HAS and PRP (Figure 3A). From the
complement system we measured C5a that showed the highest levels in plasma and C1qR1 which was
highly elevated in all cases (Figure 3B).
Figure 3. Concentration of systemic pro-inflammatory molecules (A) and complement system related
molecules (B) in blood derivatives, n = 8. The significance level was p > 0.05, where * means that
p is between 0.01 and 0.05, ** means that p is between 0.01 and 0.001, and *** means that p is lower
than 0.001.
Platelet-derived pro-inflammatory cytokines and growth factors showed a very clear pattern: they
were higher in PRP compared to other blood derivatives. In contrast, the fibrin/fibrinogen level was
high both in plasma and PRP compared to serum and HAS, as the latter two were already coagulated
and the clot was removed (Figure 4A). The anti-inflammatory cytokine IL-1RA was elevated in PRP and
HAS. Angiopoietin-1 showed the highest level in serum but was present in all other blood derivatives
in effective concentrations (Figure 4B).
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Figure 4. The concentration of platelet-derived inflammatory molecules (A) and anti-inflammatory
molecules (B) in blood derivatives, n = 8. The significance level was p > 0.05, where * means that
p is between 0.01 and 0.05, ** means that p is between 0.01 and 0.001, and *** means that p is lower
than 0.001.
3. Discussion
In the present study we investigated and compared the composition of different blood derivatives,
especially EDTA, citrate PRP and HAS. On the basis of the literature PRP has excellent regenerative
effects in numerous clinical applications, such as bone and cartilage regeneration, in osteoarthritis, in
dental and oral surgery, or in musculoskeletal regeneration [8,9,11,40]. However, there are numerous
drawbacks in the application of PRP mainly caused by certain steps of the preparation methods which
are not present in the preparation of HAS [19,20].
First, the blood derivatives were analyzed by laboratory tests, where the number of cellular
blood components, the concentration of relevant ion contents and the activity of ALP enzymes were
measured. The concentration of ions, such as iron, copper, and zinc which are all influenced by the
chelating mechanism of EDTA, were significantly lower, whereas potassium was higher in PRP and
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plasma because K3EDTA was used as an anticoagulant. The upset of the natural ionic balance due
to EDTA PRP treatment may result in unexpected side effects when using it inside injured and/or
inflamed tissue. As EDTA chelated both Zn2+ and Mg2+ the activity of ALP enzymes was reduced
significantly. ALP has an important role in bone healing and regeneration, thus the reduced enzymatic
activity has a negative effect in the case of injecting PRP into an osteoarthritic or injured joint [41].
The ionic balance of citrate PRP was much better, except for calcium ions which were added to PRP for
platelet activation, and sodium because of the addition of sodium citrate. However, a significantly
lower number of platelets could be isolated using citrate than EDTA, and the number of leukocytes
was also much higher in citrate PRP.
The standard error of mean was high, indicating that the level of red blood cells and leukocytes
in the samples depend mainly on the preparation method. During the preparation of HAS, the red
blood cell containing fraction was cut away from the bottom of the PRF clot, while in case of PRP
preparation, plasma fraction was removed by pipetting it carefully from the top of the red blood cell
containing fraction. Using this isolation procedure, the PRP fraction contains some red blood cell
fraction. The plasma isolation procedure is more complicated when citrate is used as an anticoagulant
because the plasma and red blood cell fraction overlaps after centrifugation and the boundary could
not be defined in a uniform manner. The mean platelet volume was similar in EDTA and citrate PRP,
which indicates that platelet function was not influenced significantly by EDTA in our experiments.
Using citrate, much better ionic composition can be achieved while the composition of blood shaped
elements is much less favorable than EDTA PRP. On the basis of these results, and because only EDTA
PRP was used in our previous studies for proteome profiler and luminex analysis, only EDTA PRP
and plasma were used.
The level of angiogenic proteins [35] and cytokines was screened by semi-quantitative proteome
profiler analysis. This method is not accurate enough for statistic comparison but was sufficient to
determine that the overall concentration of proteins was the highest in EDTA PRP, followed by HAS,
plasma, and the lowest was in serum. For quantitative protein measurement, inflammation-related
molecules were chosen based on the proteome profiler results and relevant scientific literature [37–39].
The level of those molecules which are derived from systemic sources and are not affected by the
preparation protocols, including MPO, ALCAM, CRP, Lipocalin-2, EMMPRIN, Osteopontin, IL-17A,
CHI3L1, CD97, CD40L, was similar. From the elements of the complement system, C5a was present in
the highest level in plasma, while C1qR1 was present in a similar concentration in all cases indicating
that it was already activated after blood drawing regardless of the processing method. Platelet-derived
pro-inflammatory cytokines and growth factors were all the highest in EDTA PRP compared to the
other blood derivatives except for fibrinogen, which was high both in plasma and EDTA PRP compared
to serum and HAS. This was due to the fibrin clot being separated from both HAS and serum after
coagulation. Analyzing the concentration of anti-inflammatory cytokines in the samples, IL-1RA was
elevated in EDTA PRP and HAS, and angiopoietin-1 was elevated in serum only. Interestingly the
platelet-derived molecules were not increased in HAS or serum, although in both cases platelets are
activated and release cytokines. This is probably due to the fact that serum is deprived of platelets
and it contains only molecules which the platelets actively secrete. This is closer to the physiological
conditions than disrupting all platelets and mixing their content into the plasma, as in the case of
EDTA PRP activated by thrombin and calcium-chloride for example. The composition analysis of
blood derivatives revealed that although the preparation method of EDTA PRP and HAS are similar,
and they are typically considered interchangeable in clinical settings, there are marked differences.
Most strikingly EDTA PRP contains excess EDTA, and as a consequence imbalanced ionic composition,
higher growth factor content, and elevated pro-inflammatory cytokine content is present compared
to HAS. According to previous results, EDTA PRP contains more angiogenic factors as well [31].
On the basis of our results so far, HAS eliminates the disadvantages of PRP preparation, such as
the addition of EDTA, citrate, thrombin, or calcium chloride, which may cause side effects inside
an injured tissue. HAS is free from activated platelets, which may be the reason why EDTA PRP is
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more pro-inflammatory than HAS. The presence of pro-inflammatory cytokines could further enhance
inflammation in injured tissues. Further benefits of using HAS instead of EDTA PRP is the better cell
proliferative effect on mesenchymal stem cells, osteoblasts, and osteoarthritic chondrocytes than EDTA
PRP based on our previous results [32,34,35].
4. Materials and Methods
4.1. Isolation of Blood Derivates
Blood samples were obtained from healthy donors of both genders aged 24–45 years under IRB
approval (IRB approval number 33106-1/2016/EKU, 12.07.2016.). The preparation method of serum,
hyperacute serum, plasma and platelet-rich plasma is shown in Figures 5–8.
Figure 5. For serum isolation, whole blood was obtained from donors in VACUETTE® 9 mL Z Serum
C/A tubes (Greiner Bio-One, Kremsmünster, Austria). Blood was allowed to clot for 30 min (a) and
centrifuged at 1710× g for 5 min at room temperature (b). The supernatant formed after centrifugation
is called serum (c,d).
Figure 6. For hyperacute serum isolation, a whole blood sample was obtained from healthy donors
(28–45 years) in VACUETTE® 9 mL Z Serum C/A tubes (Greiner Bio-One) (a) and it was immediately
centrifuged at 1710× g for 5 min at room temperature (b). After centrifugation two layers were formed
in the tubes. The top layer was the platelet-rich fibrin clot and the bottom layer contains red blood cells
(c). PRF (platelet-rich fibrin) as removed using sterile forceps in a biosafety cabinet (d), red blood cells
at the bottom of the fibrin clot were cut away (e) and the clot was placed onto a 110 mm long, 75 mm
wide custom-made plastic grid with 5 mm diameter holes on it. It was sterilized in an autoclave before
use (f). The hyperacute serum was squeezed out from the PRF clot using a sterile spatula (g,h) [24].
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Figure 7. For PRP isolation, whole blood was obtained from donors in VACUETTE® 9 mL K3 EDTA
blood collection tubes (Greiner Bio-One) and VACUTTE 3.5 mL sodium citrate 3.2% blood collection
tubes (Greiner Bio-One) (a) then centrifuged at 1710× g for 5 min at room temperature (b). The
supernatant formed after centrifugation is called plasma (c,d).
Figure 8. For PRP isolation, whole blood was obtained from donors in VACUETTE® 9 mL K3 EDTA
blood collection tubes (Greiner Bio-One) and VACUTTE 3.5 mL sodium citrate 3.2% blood collection
tubes (Greiner Bio-One) (a) then centrifuged at 320 g for 12 min at room temperature (b). The
platelet-rich layer above the buffy coat was aspirated and transferred into a 15 mL tube (c,d) and
centrifuged at 1710× g for 10 minutes (e). The resulting platelet pellet was resuspended in the same
volume as the isolated hyperacute serum from the same donor (f). PRP was activated by 10 IU thrombin
and 10 mg calcium-chloride (Sigma-Aldrich, St. Louis, MO, USA) in case of both EDTA and citrate
tubes (g,h).
4.2. Laboratory Testing of Blood Derivates
A Sysmex XN-1000 Sa-01 cell counter was used for the quantitative determination of red blood
cells, leukocytes and platelet number in the serum and plasma fractions. The concentration of ions,
that may interfere with EDTA and sodium citrate (calcium, magnesium, copper, zinc, iron, sodium,
phosphate, and potassium) and the activity of ALP enzymes were measured using a Beckman Coulter
AU5800 automated laboratory machine (n = 4).
4.3. Comprehensive Protein Analysis
In order to quantify the cytokine and angiogenesis-related protein content of EDTA PRP and
plasma serum a HAS Proteome Profiler Human Angiogenesis Array Kit (55 protein, R&D Systems,
#ARY007) (R&D Systems Inc., Minneapolis, MN, USA) [35] and Proteome Profiler Human XL Cytokine
Array Kit (102 protein R&D Systems, #ARY022) were used according to the manufacturer’s instructions.
Some cytokines were included in both the Proteome Profiler Human Angiogenesis Array Kit and
Proteome Profiler Human XL Cytokine Array Kit, in these cases we used the mean of the results.
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In total, 138 different cytokines were measured by the two different kits. Proteome Profiler individual
protein levels were measured as spot intensities on the blots using Fiji Image J 1.47 (South Bend, IN,
USA) and Adobe Photoshop CC 2015.5 software (San Jose, CA, USA). The results were expressed in %
compared to the arbitrary unit of the highest AU value, which belonged to ANG. Thus, the combined
protein level of ANG among the samples was considered to be 100% (n = 8).
4.4. Quantitative Protein Measurement by Multiplex Immunoassay and ELISA Assays
The key proteins, where clear differences were found during the proteome profiler measurements,
were quantified using custom Human Magnetic Luminex Assay (CHI3L1, C5a, EGF, CD40L, VEGF,
CRP, Il-17a, Osteopontin, Angiopoetin, IL-1RA, EMMPRIN, Lipocalin-2, Pentraxin-3, PDGF-AA,
PDGF-BB) (R&D Systems Inc.) or ELISA assays (MPO, ALCAM, CD97, C1qR1, TGF-beta, Fibrinogen,
Thrombospondin-1, CXCL-5) (Abcam, Cambridge, UK) (n = 8)
4.5. Statistical Analysis
One-way analysis of variance (ANOVA) was performed with a Tukey post hoc test to compare
differences between the groups. The significance level was p > 0.05, where * means that p is between
0.01 and 0.05, ** means that p is between 0.01 and 0.001, and *** means that p is lower than 0.001. Prism
7 software (Irvine, CA, USA) was used for statistical analysis. Data are presented as mean ± SEM.
5. Conclusions
General trends can be observed in the composition changes of the blood products that were
investigated. These trends are based on the characteristics of the additives and the steps of the
production methods. For the preparation of PRPs calcium-chloride, thrombin, citrate or EDTA is
added, which has a negative effect on the composition of these blood products. The exact mechanism
of HAS on cells is not regenerative, only acts as a supplement but with the use of HAS the negative
effects originating from the PRP’s preparation methods can be circumvented, while maintaining the
beneficial influence of PRP on cells and tissues in vitro. Our further aims include comparing the effect
of HAS, EDTA and citrate PRP in clinical studies, whicht can be differ from the in vitro results.
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